Pharming Group (PHARM) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenues rose 12% year-over-year to $74.8M, driven by strong RUCONEST and Joenja growth, with nine-month revenues up 25% to $204.5M.

• RUCONEST remains a key product with strong U.S. demand, increased new enrollments, and double-digit growth in new prescribers.

• Joenja achieved $31.9M in nine-month revenue (up 210% YoY), with global expansion, new approvals in the U.K. and Israel, and ongoing regulatory reviews in other regions.

• CEO Sijmen de Vries announced he will step down after 16 years, with a succession process underway.

• Cash and marketable securities stood at $173.3M at Q3 end, up from $161.8M at Q2 end, providing a solid liquidity position.

Financial highlights

• Q3 2024 revenues: $74.8M (+12% YoY); nine-month revenues: $204.5M (+25% YoY).

• Q3 2024 gross profit rose to $68.0M (gross margin 91%), with operating profit of $4.1M (operating margin 5.5%).

• Net loss of $1.0M in Q3 2024, compared to net profit of $3.5M in Q3 2023, due to higher finance expenses and tax.

• Nine-month 2024 net loss was $14.7M, versus $7.4M loss in the same period 2023; operating loss for nine months was $15.3M.

• Cash and marketable securities decreased to $173.3M from $215.0M at year-end 2023, mainly due to convertible bond refinancing.

Outlook and guidance

• 2024 total revenue guidance reaffirmed at $280M–$295M (14–20% growth over 2023).

• Continued growth anticipated for both RUCONEST and Joenja, with high adherence rates and stable U.S. pricing.

• Expansion into Japan, pediatric label for Joenja, and further launches in Europe, Canada, and Australia expected to drive future growth.

• Advancing Phase II trial for leniolisib in primary immune deficiencies to expand commercial potential.

• Ongoing evaluation of acquisition and in-licensing opportunities in rare diseases.